Skip to main content

Dr Camille Locht

Research Director of INSERM
contact me by email

Institute: Inserm/Institut Pasteur de Lille



My research interest is in molecular pathogenesis of respiratory infections, essentially pertussis and tuberculosis, with the long-term aim to develop new tools to combat these diseases. A very powerful molecular typing system for mycobacteria, invented in my laboratory has already reached the market, and a live attenuated nasal pertussis vaccine developed in my laboratory has now successfully completed phase I clinical trials and is currently in clinical development. I also have discovered a protective mycobacterial latency antigen, called heparin- binding haemagglutinin (HBHA), which is now in late stage pre-clinical development as an anti-tuberculosis vaccine candidate and appears also to be a powerful tool for the diagnosis of latent tuberculosis and for risk stratification of latently infected subjects


Web Links of Interest

Become a member now

Click below to find out how to become a member.